REG - OptiBiotix Health - Notice of Results

OptiBiotix HealthAnnouncement

30/04/2018 07:05

2018-04-30T06:02:15.847Zreuters.comtag:reuters.com,2018-04-30:newsml_RSd4276Ma:13TXT
This file is provided for EAP sample purposes only; it's structure and detail are subject to change, and should not be used as a definitive reference for actual development and processing.2018-04-30T06:02:15.847Z2018-04-30T06:02:15.847Z_UCDP:parsn_lse_10.54.132.131_1.2.37102:2019-05-31T06:02:15.847Z3RSd4276MaREG - OptiBiotix Health  - Notice of ResultsHealthcare (TRBC level 1)Pharmaceuticals & Medical Research (TRBC level 2)Biotechnology & Medical Research (TRBC level 4)Bio Therapeutic Drugs (TRBC level 5)Western EuropeUnited KingdomEuropeSuggested SourcesNews AnnouncementsRegulatory Corporate News AnnouncementsCompany NewsEurope daily earnings hits & missesOptiBiotix Health PLC








RNS Number : 4276M
OptiBiotix Health PLC
30 April 2018
 

OptiBiotix Health plc
("OptiBiotix" or the "Company")
 
Notice of Results
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, will announce its final results for the year ended 30 November 2017 on Wednesday, 23 May 2018.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
For further information, please contact:
 
 




OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below














Cairn Financial Advisers LLP (NOMAD)


Tel: 020 7213 0880




Liam Murray / Jo Turner








 
finnCap (Broker)


 
Tel: 020 7220 0500




Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)








Abigail Wayne (Corporate Broking)


















Walbrook PR Ltd


Tel: 020 7933 8780 or optibiotix@walbrookpr.com




Anna Dunphy


Mob: 07876 741 001









 
 
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
 



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORLLFLFSLIDFIT